Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its ...

In order to have the flexibility to opportunistically allocate excess capital to share repurchases, today the Company announced that its Board of Directors has authorized a new share repurchase plan ...

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced ...

Fort Lauderdale, Florida, USA, November 18, 2025 – HelixAI, a life science AI company creating an agentic operating system to transform R&D, launches its first-in-class agentic OS today at the AI ...

Data to be presented at an upcoming medical meeting and shared with health authorities around the world Basel, 18 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase III ...

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse ...

Syngenta and Amoeba SA to develop and commercialize biocontrol solutions for EU and UK ...

Invivyd intends to use the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents, for commercial preparedness for the potential launch of VYD2311, ...

Portsmouth Square, Inc. owns the Hilton San Francisco Financial District (558 rooms) with extensive meeting space, restaurant and lounge, and a five-level parking garage. The hotel operates under a ...

ART-501, formerly known as ARD-501 or TLX-032 for Tulex, is a proprietary oral liquid extended-release formulation of an existing, well-tolerated opioid receptor modulating drug developed through a ...

WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, ...

This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and ...